Evaluate Vantage Homepage

Vantage logo

Abbvie takes its Treg cue

The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.


Company Events

Vantage logo

Pressure piles up on pamrevlumab

After the latest roxadustat clanger a phase 3 interim analysis in pancreatic cancer becomes even more important for Fibrogen.


Vantage logo

Freenome aims to take on the big beasts

Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.